| scholarly article | Q13442814 |
| P50 | author | Anna K. Nowak | Q40897391 |
| David Fielding | Q42293023 | ||
| Bill Musk | Q99566706 | ||
| P2093 | author name string | P Mitchell | |
| A Segal | |||
| R Williamson | |||
| G Ryan | |||
| M J Byrne | |||
| B W S Robinson | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. | Q31878746 | ||
| Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma | Q33180838 | ||
| A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group | Q33329248 | ||
| Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Q33329809 | ||
| Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients | Q33332579 | ||
| A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma | Q33334777 | ||
| Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study | Q33498199 | ||
| Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer | Q33498591 | ||
| Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer | Q33499691 | ||
| Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery | Q33503531 | ||
| Advances in the treatment of malignant pleural mesothelioma | Q33715899 | ||
| A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group | Q34295028 | ||
| Chemotherapy in malignant pleural mesothelioma. A review. | Q38563914 | ||
| Continuing increase in mesothelioma mortality in Britain. | Q40991450 | ||
| Preclinical combination therapy with gemcitabine and mechanisms of resistance | Q41189890 | ||
| Predictions of future cases of asbestos-related disease among former miners and millers of crocidolite in Western Australia. | Q41211074 | ||
| Interaction between cisplatin and gemcitabine in vitro and in vivo. | Q41322634 | ||
| A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study | Q43997685 | ||
| Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. | Q53517685 | ||
| One-sample multiple testing procedure for phase II clinical trials | Q70365924 | ||
| The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer | Q73209597 | ||
| Phase II study of vinorelbine in patients with malignant pleural mesothelioma | Q73250833 | ||
| Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors | Q73273800 | ||
| The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer | Q77204463 | ||
| Phase II trial of high-dose cisplatin in patients with malignant mesothelioma | Q93608717 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| cisplatin | Q412415 | ||
| P304 | page(s) | 491-496 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma | |
| P478 | volume | 87 |
| Q44649986 | A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma |
| Q33378432 | A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. |
| Q33414357 | A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma |
| Q33812537 | A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma |
| Q42599445 | A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q35074838 | Chemotherapy for malignant pleural mesothelioma: past results and recent developments |
| Q52672893 | Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. |
| Q39963783 | Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. |
| Q35967314 | Current chemotherapeutic treatment of malignant pleural mesothelioma |
| Q59132464 | Current chemotherapy strategies in malignant pleural mesothelioma |
| Q37232309 | Current therapies for malignant pleural mesothelioma |
| Q41847770 | FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q37243005 | Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810) |
| Q33378691 | Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma |
| Q36322368 | Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients |
| Q33400437 | Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals |
| Q34616107 | Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. |
| Q34618985 | Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma |
| Q80510543 | Lung cancer |
| Q80961479 | Malignant mesothelioma |
| Q37261327 | Malignant mesothelioma after household exposure to asbestos |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q83412919 | Malignant pleural mesothelioma |
| Q35740408 | Malignant pleural mesothelioma--an update |
| Q40041012 | Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data. |
| Q33686248 | Malignant pleural mesothelioma: a single-center experience in Turkey |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q37217764 | Malignant pleural mesothelioma: current and future perspectives |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q38215513 | Management of malignant pleural mesothelioma-The European experience |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q79968444 | Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors |
| Q36097706 | Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma |
| Q43466291 | Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. |
| Q36780582 | Newer issues in mesothelioma chemotherapy. |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q35117095 | Pemetrexed and its emerging role in the treatment of thoracic malignancies |
| Q36118385 | Pemetrexed-cisplatin combination in mesothelioma |
| Q34402081 | Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. |
| Q44647820 | Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma |
| Q50665635 | Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. |
| Q53184110 | Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. |
| Q34622818 | Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials |
| Q51114246 | The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. |
| Q35686558 | The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma |
| Q59132459 | The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey |
| Q46988434 | Triplet chemotherapy for malignant pericardial mesothelioma: a case report |
| Q35129531 | Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. |
Search more.